Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
PACB
Pacific Biosciences of CaliforniaNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$419.62M
P/E Ratio
—
EPS
$-0.42
Beta
2.31
52W High
$2.73
52W Low
$1.07
50-Day MA
$1.40
200-Day MA
$1.64
Dividend Yield
—
Profit Margin
-82.50%
Forward P/E
—
PEG Ratio
-0.17
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
Fundamentals
| Revenue (TTM) | $159.27M |
| Gross Profit (TTM) | $46.86M |
| EBITDA | $199.18M |
| Operating Margin | -114.40% |
| Return on Equity | -929.00% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.52 |
| Book Value | $-0.11 |
| Price-to-Book | 170.66 |
| Price-to-Sales (TTM) | 2.63 |
| EV/Revenue | 5.47 |
| EV/EBITDA | 140.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $310.83M |
| Float | $304.01M |
| % Insiders | 8.91% |
| % Institutions | 55.47% |
Historical Volatility
HV 10-Day
118.74%
HV 20-Day
102.97%
HV 30-Day
98.06%
HV 60-Day
84.13%
HV Rank
86.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($2.29 target)
4
Buy2
Hold1
Strong SellLatest News
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
GlobeNewsWire9/3/2026Neutral
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Zacks Investment Research9/2/2026Negative
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
24/7 Wall Street8/25/2026Positive
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Zacks Investment Research8/6/2026Negative
Pacific Biosciences: It's Only Getting Worse
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.
Seeking Alpha8/6/2026Negative
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition and lowering its full-year revenue outlook amid a slower-than-expected rollout of its new multi-use sequencing chemistry and continued funding constraints in academic and government markets.
MarketBeat8/6/2026Positive
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026
GlobeNewsWire8/5/2026Neutral
PacBio Announces Second Quarter 2026 Financial Results
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.
GlobeNewsWire8/5/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PACB and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026